Bausch Health Cos (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with a focus on gastroenterology, neurology, dermatology and other specialty therapeutic areas.

Its portfolio includes gastrointestinal treatments such as Xifaxan, Trulance and Relistor, as well as products for conditions affecting the central nervous system and skin. Bausch Health also markets the Solta Medical portfolio of aesthetic medical devices. Its former eye-health business, Bausch + Lomb, was separated from Bausch Health as an independent publicly traded company in 2022.

The company traces its history to Valeant Pharmaceuticals International and adopted the Bausch Health name in 2018. Bausch Health serves patients and healthcare providers through operations and commercial activities in North America and international markets. Thomas J. Appio serves as the company's chief executive officer.

Key Stats

• Today's Range: $5.84 to $6.13
• 50-Day Range: $4.43 to $7.01
• 52-Week Range: $4.33 to $8.00
• Volume: 2.40 million shs
• Average Volume: 2.60 million shs
• Market Capitalization: $2.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Reduce

Bausch Health Cos Stock Analysis - MarketRank™

Bausch Health Cos scored higher than 58% of companies evaluated by MarketBeat, and ranked 420th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Reduce

Consensus Rating

Bausch Health Cos has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Bausch Health Cos has a consensus price target of $8.00, representing about 36.6% upside from its current price of $5.86.

Amount of Analyst Coverage

Bausch Health Cos has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -7.59%

Earnings Growth

Earnings for Bausch Health Cos are expected to decrease by -7.59% in the coming year, from $4.35 to $4.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Cos is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Cos is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bausch Health Cos has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.77% of the float of Bausch Health Cos has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Cos has a short interest ratio ("days to cover") of 2.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Cos has recently decreased by 2.33%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch Health Cos does not currently pay a dividend.

Dividend Growth

Bausch Health Cos does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.04

News Sentiment

Bausch Health Cos has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Bausch Health Cos this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,894.00 in company stock.

Percentage Held by Insiders

20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/12/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BHC
• CIK: 885590
• Web: www.bauschhealth.com
• Phone: (514) 744-6792
• Fax: 514-744-6272
• Employees: 20,300
• Year Founded: 1959

Price Target and Rating

• Average Price Target for Bausch Health Cos: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: +36.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.35
• P/E Growth: N/A
• Net Income: $157 million
• Net Margins: -10.12%
• Pretax Margin: -6.74%
• Return on Equity: -561.95%
• Return on Assets: 6.31%

Debt

• Debt-to-Equity Ratio: 54.68
• Current Ratio: 1.44
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $10.27 billion
• Price / Sales: 0.21
• Cash Flow: $7.05 per share
• Price / Cash Flow: 0.83
• Book Value: $1.02 per share
• Price / Book: 5.74

Miscellaneous

• Outstanding Shares: 374,140,000
• Free Float: 296,805,000
• Market Cap: $2.19 billion
• Optionable: Optionable
• Beta: 0.37